Physician-scientist Charles M. Rudin, Chief of the Thoracic Oncology Service, leads research that focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models including patient-derived xenografts. These studies are integrated with early phase clinical trials.
Charles M. Rudin, MD, PhD
Professor
Research Focus
Physician-scientist Charles Rudin focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models.Education
MD, PhD, University of Chicago Pritzker School of MedicineLab Members
Senior Research Technician
Postdoctoral Researcher
Graduate Student
Graduate Student
Research Assistant/Lab Manager
Thoracic Oncology Fellow
Medical Oncology Fellow
Graduate Student
Assistant Attending, Thoracic Oncology Service
Assistant Attending, Thoracic Oncology Service
Assistant Attending/Lab Co-Director
Graduate Student
Research Technician
Research Fellow
Publications
- Ruscetti M, Leibold J, Bott MJ, Fennell M, Kulick A, Salgado NR, Chen CC, Ho YJ, Sanchez-Rivera FJ, Feucht J, Baslan T, Tian S, Chen HA, Romesser PB, Poirier JT, Rudin CM, de Stanchina E, Manchado E, Sherr CJ, Lowe SW. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science. 362(6421):1416-1422. 2018.
- Laird JH, Lok BH, Ma J, Bell A, de Stanchina E, Poirier JT, Rudin CM. Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts. Clin Cancer Res. 24(20):5143-5152. 2018.
